Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALKS

Alkermes plc

Dec 10 • 04:00PM ET

28.62

+0.18 0.63 %

Healthcare • Drug Manufacturers - Specialty & Generic • Ireland • NASD

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR VTI VB IWM AVUV XBI VBK VXF SPSM FBT

Scroll to Statements

Index	RUT	P/E	14.16	EPS (ttm)	2.02	Insider Own	2.24%	Shs Outstand	165.10M	Perf Week	-3.08%
Market Cap	4.73B	Forward P/E	17.45	EPS next Y	1.64	Insider Trans	-0.69%	Shs Float	161.42M	Perf Month	-12.34%
Enterprise Value	3.69B	PEG	-	EPS next Q	0.42	Inst Own	103.94%	Short Float	11.67%	Perf Quarter	3.28%
Income	338.83M	P/S	3.11	EPS this Y	-41.60%	Inst Trans	1.22%	Short Ratio	8.01	Perf Half Y	-8.27%
Sales	1.52B	P/B	2.73	EPS next Y	-2.82%	ROA	15.08%	Short Interest	18.83M	Perf YTD	-0.49%
Book/sh	10.50	P/C	4.25	EPS next 5Y	-24.73%	ROE	22.35%	52W High	36.45 -21.48%	Perf Year	-9.03%
Cash/sh	6.73	P/FCF	9.63	EPS past 3/5Y	- -	ROIC	18.84%	52W Low	25.17 13.73%	Perf 3Y	20.69%
Dividend Est.	-	EV/EBITDA	9.48	Sales past 3/5Y	9.89% 5.87%	Gross Margin	85.66%	Volatility	2.96% 4.09%	Perf 5Y	62.04%
Dividend TTM	-	EV/Sales	2.42	EPS Y/Y TTM	3.40%	Oper. Margin	23.57%	ATR (14)	1.19	Perf 10Y	-58.03%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	1.08%	Profit Margin	22.27%	RSI (14)	42.89	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	3.67	EPS Q/Q	-11.21%	SMA20	-2.11%	Beta	0.48	Target Price	43.88
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	4.24%	SMA50	-5.91%	Rel Volume	0.94	Prev Close	28.44
Employees	1800	LT Debt/Eq	0.04	Earnings	Oct 28 BMO	SMA200	-4.47%	Avg Volume	2.35M	Price	28.62
IPO	Jul 16, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	85.55% 10.45%	Trades		Volume	2,209,134	Change	0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-25	Initiated	Truist	Buy	$50
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$44
Sep-03-25	Initiated	Wells Fargo	Overweight	$44
Jul-15-25	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35

Show Previous Ratings

Dec-08-25 09:40AM	Are Investors Undervaluing Alkermes (ALKS) Right Now? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-25-25 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
04:22PM	Loading…
Nov-19-25 04:22PM	Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck (Investor's Business Daily)
01:44PM	Alkermes prevails over Lundbeck in Avadel bidding war (Pharmaceutical Technology)
10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
09:12AM	Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks (Zacks)
08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
06:00AM	Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc (PR Newswire)
05:33AM	Alkermes escalates bidding war; US biotech risks falling behind China (BioPharma Dive)
12:25AM	TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment (Insider Monkey)
Nov-18-25 01:23PM	RHHBY Reports Positive Phase III Data on Breast Cancer Drug (Zacks)
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
10:36AM	Loading…
10:36AM	Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal (Zacks)
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks)
Nov-14-25 12:39PM	Health Care Roundup: Market Talk (The Wall Street Journal) -6.35%
11:38AM	To Wall Street, a new bidding war puts Alkermes in a tough spot (BioPharma Dive)
09:40AM	H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal (The Wall Street Journal)
09:19AM	Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid (Investor's Business Daily)
08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
07:45AM	Alkermes Response to Avadel Announcement (PR Newswire)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-12-25 12:16PM	Narcolepsy race heats up with Alkermes OX2R NT2 data but investors spooked (Clinical Trials Arena) -7.11%
09:35AM	DraftKings downgraded, Instacart upgraded: Wall Streets top analyst calls (TipRanks)
07:30AM	Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 (PR Newswire)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
11:40AM	ALKS or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	Loading…
09:32AM	DraftKings downgraded, Instacart upgraded: Wall Street's top analyst calls (The Fly)
09:00AM	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates (Zacks)
Nov-07-25 01:45PM	IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y (Zacks)
01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks)
09:55AM	Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? (Zacks)
Nov-06-25 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
01:59PM	Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:40AM	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks)
Nov-05-25 02:18PM	Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut (Zacks)
10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:00AM	FORM 8.1(a) & (b) (Opening Position Disclosure) (PR Newswire)
Nov-04-25 08:38AM	HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline (Zacks)
Oct-31-25 10:20AM	GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow (Zacks)
08:58AM	Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake (Zacks)
Oct-30-25 03:05PM	Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion (GuruFocus.com)
10:32AM	BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View (Zacks)
10:28AM	BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales (Zacks)
Oct-29-25 01:45PM	Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised (Zacks)
Oct-28-25 02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
11:00AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
08:20AM	Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
07:16AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-27-25 09:25AM	Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result (GuruFocus.com)
Oct-23-25 02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:27AM	ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition (Zacks)
09:39AM	LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls (The Fly)
05:25AM	Alkermes to acquire Avadel for $2.1bn (Pharmaceutical Technology)
Oct-22-25 04:11PM	Why Alkermes' $2.1 Billion Avadel Buyout Was 'Very Confusing' - At First (Investor's Business Daily)
07:36AM	Alkermes expands sleep portfolio with acquisition worth up to $2.1B (BioPharma Dive)
07:00AM	Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc (PR Newswire)
Oct-21-25 11:40AM	ALKS vs. RGEN: Which Stock Is the Better Value Option? (Zacks)
09:55AM	Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know (Zacks)
09:40AM	Is Alkermes (ALKS) Stock Undervalued Right Now? (Zacks)
09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
Oct-20-25 04:00PM	Alkermes to Report Third Quarter Financial Results on October 28, 2025 (PR Newswire)
Oct-07-25 09:25AM	Do Options Traders Know Something About Alkermes Stock We Don't? (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-18-25 12:39PM	HC Wainwright Affirms Alkermes (ALKS) 'Neutral' Rating on Vibrance-1 Phase 2 Study (Insider Monkey)
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
Sep-12-25 09:00AM	Alkermes Appoints Joshua Reed as Chief Financial Officer (PR Newswire)
Sep-11-25 07:00AM	Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards Program (PR Newswire)
Sep-10-25 11:30AM	Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-08-25 05:19PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:12PM	Takeda and Alkermes share OX2R drug data for narcolepsy (Clinical Trials Arena)
03:15AM	Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 (PR Newswire)
Sep-03-25 11:30AM	Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 03:45AM	Alkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025 (Insider Monkey)
Aug-28-25 11:30AM	Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report? (Zacks)
Aug-25-25 07:00AM	Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 (PR Newswire)
Aug-20-25 12:52PM	Xoma, a drug royalty specialist, buys another zombie biotech (BioPharma Dive)
Jul-31-25 01:01AM	ALKS- Positive Narcolepsy Drug Trial Puts this Biotech Name in Focus (MoneyShow) -5.16%
Jul-30-25 10:23AM	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
Jul-29-25 09:30AM	Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:25AM	Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:21AM	Alkermes: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 10:36AM	CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? (Zacks)
09:23AM	Alkermes PLC (ALKS) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-24-25 12:10PM	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-23-25 10:53AM	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? (Zacks)
10:00AM	GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-22-25 10:00AM	Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Option Exercise	19.34	3,748	72,486	69,488	Dec 05 04:21 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Sale	30.00	3,748	112,447	65,740	Dec 05 04:21 PM
Hopkinson Craig C.	Officer	Dec 03 '25	Proposed Sale	30.00	3,748	112,447		Dec 03 04:32 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 01 '25	Sale	29.30	4,000	117,200	65,740	Dec 01 05:41 PM
Hopkinson Craig C.	Officer	Dec 01 '25	Proposed Sale	29.30	4,000	117,200		Dec 01 04:45 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Option Exercise	19.34	5,000	96,700	78,740	Nov 03 04:37 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Sale	30.38	9,000	273,442	69,740	Nov 03 04:37 PM
Hopkinson Craig C.	Officer	Nov 03 '25	Proposed Sale	30.38	9,000	273,442		Nov 03 04:35 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Option Exercise	19.34	5,000	96,700	82,740	Oct 15 06:47 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Sale	31.53	9,000	283,776	73,740	Oct 15 06:47 PM
Hopkinson Craig C.	Officer	Oct 15 '25	Proposed Sale	31.53	9,000	283,777		Oct 15 04:07 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 09 '25	Sale	31.95	3,333	106,489	89,542	Jun 10 04:39 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 10 '25	Sale	31.09	3,334	103,654	86,208	Jun 10 04:39 PM
Nichols Christian Todd	Officer	Jun 10 '25	Proposed Sale	31.09	3,334	103,654		Jun 10 04:29 PM
Nichols Christian Todd	Officer	Jun 09 '25	Proposed Sale	31.95	3,333	106,489		Jun 09 04:08 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 28 '25	Sale	34.00	1,938	65,892	7,717	Feb 28 05:19 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 25 '25	Sale	35.26	3,743	131,978	7,717	Feb 25 06:38 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 20 '25	Sale	35.69	1,327	47,361	7,717	Feb 20 05:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Option Exercise	30.12	144,419	4,350,097	202,294	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Option Exercise	19.64	199,196	3,912,871	262,796	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 12 '25	Sale	32.78	204,921	6,718,278	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 13 '25	Sale	35.53	144,419	5,130,698	57,875	Feb 14 05:12 PM
Hopkinson Craig C.	Officer	Feb 13 '25	Proposed Sale	35.53	144,419	5,130,694		Feb 13 04:36 PM
Hopkinson Craig C.	Officer	Feb 12 '25	Proposed Sale	32.78	204,921	6,718,276		Feb 12 04:19 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Option Exercise	22.22	97,632	2,169,137	145,208	Jan 31 08:42 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 30 '25	Sale	32.05	100,918	3,234,382	44,290	Jan 31 08:42 PM
Hopkinson Craig C.	Officer	Jan 30 '25	Proposed Sale	32.05	100,918	3,234,380		Jan 30 05:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS

Alkermes plc

Upgrade your FINVIZ experience